Robert Crawford

Robert Crawford is a partner in the firm’s Technology Companies & Life Sciences group and is a leader in the firm’s generic pharmaceutical transactions practice. Robert represents technology, pharmaceutical and other life science companies in connection with their commercial, M&A, royalty monetization, acquisitions and financings, and intellectual property transactions, including complex strategic collaboration, co-development, licensing and partnering transactions. He also has extensive experience structuring and negotiating brand, generic and biosimilar settlement and license agreements related to Hatch-Waxman and BPCIA patent disputes.